## Thierry Durand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2599486/publications.pdf

Version: 2024-02-01

22 1,081 papers citations

18 h-index 22 g-index

22 all docs

22 docs citations 22 times ranked 1318 citing authors

#	Article	IF	CITATIONS
1	Effect of Dietary <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>n</mml:mi><mml:mo><mml:mn>3</mml:mn></mml:mo></mml:math> Source on Rabbit Male Reproduction. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-13.	4.0	34
2	Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25 years of research in chemistry and biology. Progress in Lipid Research, 2017, 68, 83-108.	11.6	130
3	Rett syndrome: An autoimmune disease?. Autoimmunity Reviews, 2016, 15, 411-416.	5.8	25
4	Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome. Neuroscience Research, 2016, 105, 28-34.	1.9	7
5	Non-enzymatic cyclic oxygenated metabolites of omega-3 polyunsaturated fatty acid: Bioactive drugs?. Biochimie, 2016, 120, 56-61.	2.6	29
6	MECP2 Duplication Syndrome: Evidence of Enhanced Oxidative Stress. A Comparison with Rett Syndrome. PLoS ONE, 2016, 11, e0150101.	2.5	22
7	Oxidative stress: a hallmark of Rett syndrome. Future Neurology, 2015, 10, 179-182.	0.5	4
8	Cytokine Dysregulation in <i>MECP2 </i> - and <i>CDKL5 </i> -Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and <i>I'm </i> -3 PUFAs. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-18.	4.0	61
9	Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α-linolenic acids; bioactivities and potential use as biomarkers. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 446-455.	2.4	51
10	Redox Imbalance and Morphological Changes in Skin Fibroblasts in Typical Rett Syndrome. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-10.	4.0	44
11	Effects of <b><i>i'&gt;   Work of the content of the c</i></b>	3.0	18
12	Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: Effects of omega-3 polyunsaturated fatty acid supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids, 2014, 91, 183-193.	2.2	25
13	Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. Neurobiology of Disease, 2014, 68, 66-77.	4.4	118
14	Isoprostanes and neuroprostanes: Total synthesis, biological activity and biomarkers of oxidative stress in humans. Prostaglandins and Other Lipid Mediators, 2013, 107, 95-102.	1.9	72
15	F2-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. Biochimie, 2013, 95, 86-90.	2.6	30
16	Erythrocyte Shape Abnormalities, Membrane Oxidative Damage, and $\langle i \rangle \hat{i}^2 \langle i \rangle$ -Actin Alterations: An Unrecognized Triad in Classical Autism. Mediators of Inflammation, 2013, 2013, 1-11.	3.0	35
17	Effects of <b><i>i'&gt; i'&gt; ' b&gt;&lt;3 Polyunsaturated Fatty Acids on Plasma Proteome in Rett Syndrome.  Mediators of Inflammation, 2013, 2013, 1-9.</i></b>	3.0	12
18	Isoprostanes and 4-Hydroxy-2-nonenal: Markers or Mediators of Disease? Focus on Rett Syndrome as a Model of Autism Spectrum Disorder. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-10.	4.0	36

## THIERRY DURAND

#	Article	IF	CITATION
19	Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. Genes and Nutrition, 2012, 7, 447-458.	2.5	76
20	The role of oxidative stress in Rett syndrome: an overview. Annals of the New York Academy of Sciences, 2012, 1259, 121-135.	3.8	95
21	F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. Journal of Lipid Research, 2011, 52, 2287-2297.	4.2	93
22	Oxidative stress in Rett syndrome: Natural history, genotype, and variants. Redox Report, 2011, 16, 145-153.	4.5	64